NASDAQ •
Healthcare •
Biotechnology •
Quote as of 06/18/2026
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization1,336.66 mln
Float69.59 mln
Earnings Date08/19/2026
Piotroski F-Score
2
/ 9
Weak
Beneish M-Score
-1.76
Likely manipulated
1-Year Forecast
18.77
Transformational upside
Relative Strength
26
/ 100
Underperforming
Debt / Equity
0.03
Debt-free
ROE
-46.15
Deeply negative
Business Description
Immatics N.V. is a Germany-based company working to develop new cancer treatments that harness the power of the immune system, with a particular focus on hard-to-treat solid tumors. The company is advancing several therapies through clinical trials, including cell-based treatments and a class of precision proteins designed to direct immune cells toward cancer. To support its research, Immatics has formed partnerships with leading organizations such as MD Anderson Cancer Center, Celgene, and Genmab.
